Data updated: Jun 28, 2026
Diarrhea Clinical Trial Landscape
Diarrhea is being studied across 222 clinical trials registered since 2008, with 34 programs currently active. The competitive pipeline includes 7 active Phase 3 trials, 12 active Phase 2 trials, and 6 active Phase 1 trials.
Trial activity
34 active / 222 total since 2008
Active by phase 7 Ph3 / 63 12 Ph2 / 80 6 Ph1 / 23 9 Ph4 / 56
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Bausch Health Americas, Inc. 1 3 0
Crinetics Pharmaceuticals Inc. 1 1 0
Tasly Pharmaceutical Group Co., Ltd 1 1 0
Eli Lilly 1 0 0
Vedanta Biosciences, Inc. 1 0 0
Shanghai United Cell Biotechnology Co., Ltd 1 0 0
Inventprise Inc. 1 0 0
Biocodex 1 0 0
Leeuwenhoek Laboratories Co. Ltd. 1 0 0
Novartis 0 3 1
Intercell USA, Inc. 0 4 0
Menarini Group 0 2 2
Bio-K Plus International Inc. 0 2 1
How the field has grown
New-trial starts peaked in 2019 (19 registered); 2025 saw 11. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (22 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 9
2017 14
2018 16
2019 19
2020 8
2021 6
2022 7
2023 9
2024 9
2025 11
2026 11
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (3) 233
2017 (1) 8,268
2018 (3) 124
2019 (5) 450
2020 (2) 404
2021 (0) 0
2022 (0) 0
2023 (2) 498
2024 (3) 852
2025 (2) 274
2026 (1) 636
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07087054 RECRUITING
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Crinetics Pharmaceuticals Inc. n=141
NCT06237452 RECRUITING
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Vedanta Biosciences, Inc. n=852
NCT07168434 RECRUITING
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
Biocodex n=406
NCT05519254 RECRUITING
Lactoferrin and Lysozyme Supplementation for Long-term Diarrhea Sequelae
University of Washington n=600
NCT06247046 RECRUITING
A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D
Guangzhou Zhiyi Biotechnology Co., Ltd. n=1,298
NCT06753890 NOT YET RECRUITING
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
Tasly Pharmaceutical Group Co., Ltd n=520
NCT07610434 NOT YET RECRUITING
Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)
Beijing Hospital of Traditional Chinese Medicine n=636
NCT05814042 COMPLETED
Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea
University of Florida n=396
NCT03535272 TERMINATED
Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
Centers for Disease Control and Prevention n=482
NCT01375647 COMPLETED
Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
University of Vermont n=700
NCT03851835 COMPLETED
Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis
University of Calgary n=1,030
NCT04538625 COMPLETED
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
Napo Pharmaceuticals, Inc. n=287
NCT03473561 COMPLETED
Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea
Abbott n=31
NCT04132375 TERMINATED
Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS
Inmunova S.A. n=11
NCT02819960 COMPLETED
Prevention of Irinotecan Induced Diarrhea by Probiotics
S&D Pharma SK s.r.o. n=233
NCT04321460 COMPLETED
Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.
Sandoz n=520
NCT03703336 COMPLETED
Phase III Study of Liquid Formulation of ROTAVIN
Center for Research and Production of Vaccines and Biologicals, Vietnam n=825
NCT03602053 COMPLETED
Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia
Centre for Infectious Disease Research in Zambia n=450
NCT01371656 COMPLETED
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Children's Oncology Group n=624
NCT04065529 COMPLETED
Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO)
Ferrer Internacional S.A. n=150
NCT01374490 COMPLETED
Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
Bausch Health Americas, Inc. n=250
NCT03130114 COMPLETED
Antibiotics for Children With Severe Diarrhoea
World Health Organization n=8,268
NCT01198145 COMPLETED
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy
Alliance for Clinical Trials in Oncology n=87
NCT02498418 COMPLETED
Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea
Actavis Inc. n=739
NCT03463512 COMPLETED
Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea
Abbott n=124
NCT02920242 TERMINATED
A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.
Sandoz n=28
NCT01208922 COMPLETED
Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea
Dr. Falk Pharma GmbH n=835
NCT00891371 COMPLETED
Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea
Ipsen n=42
NCT02280044 COMPLETED
Efficacy of Rifaximin in Preventing Campylobacteriosis
Johns Hopkins Bloomberg School of Public Health n=30
NCT01142089 COMPLETED
Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)
Cosmo Technologies Ltd n=264
NCT01543178 COMPLETED
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
Bausch Health Americas, Inc. n=2,583
NCT02736539 WITHDRAWN
Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea
Clasado Biosciences Ltd
NCT02538692 COMPLETED
Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome
Chengdu University of Traditional Chinese Medicine n=160
NCT01358708 TERMINATED
Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
Forest Laboratories n=26
NCT02120027 TERMINATED
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Menarini Group n=558
NCT02107196 COMPLETED
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Menarini Group n=535
NCT01832636 COMPLETED
Intervention and Mechanisms of Alanyl-Glutamine for Inflammation, Nutrition, and Enteropathy
Children's Hospital Medical Center, Cincinnati n=112
NCT01143272 TERMINATED
Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea
Bernhard Nocht Institute for Tropical Medicine n=477
NCT02320318 WITHDRAWN
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Menarini Group
NCT02239926 TERMINATED
Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D
Mayo Clinic n=5
NCT02642250 COMPLETED
Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea
Shifa Ul Mulk Memorial Hospital n=70
NCT01870895 COMPLETED
A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)
Astellas Pharma Inc n=577
NCT01736423 COMPLETED
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
Astellas Pharma Inc n=151
NCT01968408 COMPLETED
Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children
Medical University of Warsaw n=184
NCT00582426 COMPLETED
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Novartis Pharmaceuticals n=139
NCT01350570 COMPLETED
Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial
Chengdu University of Traditional Chinese Medicine n=449
NCT01837940 COMPLETED
Efficacy of a Dietary Supplementation With Lactobacillus Reuteri for Digestive Health in an Elderly Population
Örebro University, Sweden n=290
NCT01531218 COMPLETED
Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea
University of Aarhus n=100
NCT01100684 COMPLETED
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
Tioga Pharmaceuticals n=611
NCT01295918 COMPLETED
Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children
St Marina University Hospital, Varna, Bulgaria n=100
NCT00705445 COMPLETED
Evaluation of Zinc and / or Micronutrient Supplementation on Intestinal Flora, Diarrheal Disease Burden, Intestinal Mucosal Integrity and Growth Among Children of Pakistan
Aga Khan University n=2,745
NCT00826137 COMPLETED
Preventing Childhood Antibiotic-associated Diarrhea by Prebiotics
Soroka University Medical Center n=200
NCT00993681 COMPLETED
Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study
Intercell USA, Inc. n=2,036
NCT00958308 COMPLETED
Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection
Bio-K Plus International Inc. n=255
NCT01046656 COMPLETED
L Reuteri for the Prevention of Nosocomial Diarrhea
Medical University of Warsaw n=106
NCT01502969 COMPLETED
Safety and Immunogenicity Assessment of Rotavin-M1 in Vietnamese Children
National Institute of Hygiene and Epidemiology, Vietnam n=799
NCT00560222 COMPLETED
Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) n=555
NCT01143623 COMPLETED
Dose Response Effect of Probiotics for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults
Changhai Hospital n=510
NCT00760851 COMPLETED
Yogurt Study in Children 2-4 Years Old Attending Daycare
Georgetown University n=190
NCT00737412 COMPLETED
Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults
Bio-K Plus International Inc. n=277
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only